Abstracts tagged "RANK/RANKL pathway"

Abstract Number: 356 • 2015 ACR/ARHP Annual Meeting
Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases
Kosuke Ebina¹, Makoto Hirao², Jun Hashimoto³, Keisuke Hagihara⁴, Hideki Yoshikawa⁵ and Takaaki Noguchi⁶, ¹Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, ²Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Suita, Japan, ³Dept of Rheumatology, Osaka-Minami Medical Center, Kawachinagano City, Japan, ⁴Kampo Medicine, Osaka University, Graduate School of Medicine, Suita, Japan, ⁵Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ⁶Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan
Background/Purpose: In patients with rheumatic diseases (RD), pro-inflammatory cytokines induce receptor activator of nuclear factor kappa-B ligand (RANKL), which plays a crucial role in inducing…
Abstract Number: 2085 • 2015 ACR/ARHP Annual Meeting
DC-STAMP Regulates Osteoclastogenesis through the Ca2+ /NFATc1 Axis
Yahui Grace Chiu¹, Dongge Li², Yue-Xin Xu³, Tzong-Ren Sheu⁴, Minsoo Kim⁵ and Christopher T. Ritchlin⁶, ¹Allergy, Immunology, and Rheumatology, University of Rochester, Rochester, NY, ²Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ³Microbiology & Immunology, University of Rochester, Rochester, NY, ⁴Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ⁵Microbiology and Immunology, University of Rochester, Rochester, NY, ⁶Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Osteoclasts (OC) are the only cell type known to erode bone. Many bone diseases including osteoporosis and arthritis are caused by excessive OC activity.…
Abstract Number: 2622 • 2015 ACR/ARHP Annual Meeting
Serum RANKL Levels, Associate with Anti Citrullinated Proteins Antibodies (ACPA) in Early-Untreated Rheumatoid Arthritis and Is Modulated Following Methotrexate
Aase Haj Hensvold¹, Vijay Joshua¹, K. Lundberg², Nadine A. Defranoux³, Saedis Saevarsdottir⁴ and Anca I Catrina², ¹Rheumatology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Department of Medicine, Rheumatology Unit, The Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Receptor Activator of Nuclear factor Kappa-b Ligand (RANKL) is a key regulator of bone metabolism. Anti-citrullinated (cit) protein antibodies (ACPA) have been suggested to…
Abstract Number: 2716 • 2015 ACR/ARHP Annual Meeting
Dysregulated Osteoclastogenesis Is Related to Natural Killer T Cell Dysfunction in Rheumatoid Arthritis
Seung-Jung Kee¹, Hye Mi Jin², Jeong-Hwa Kang², Young-Nan Cho², Ki-Jeong Park², Hyun-Ju Jung² and Yong-Wook Park², ¹Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, South Korea, ²Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: The aims of the present study were to investigate the role played by natural killer T (NKT) cells in osteoclastogenesis and their effects on…
Abstract Number: 330 • 2014 ACR/ARHP Annual Meeting
Prolactin Reduces Bone Erosion in Adjuvant-Induced Arthritis
Maria G. Ledesma-Colunga, Norma Adan, Ana L. Reyes-Lopez, Fernando Lopez-Barrera, Gonzalo Martinez de la Escalera and Carmen Clapp, Institute of Neurobiology, National University of Mexico (UNAM), Queretaro, Mexico
Background/Purpose Bone erosion is an important feature of rheumatoid arthritis (RA) that frequently results in lifelong crippling. The receptor activator of NFkB ligand (RANKL)/osteoprotegerin (OPG)/RANK…
Abstract Number: 238 • 2014 ACR/ARHP Annual Meeting
RANKL and OPG Gene Polymorphisms: Association with Vertebral Fractures and Bone Mineral Density in Premenopausal Systemic Lupus Erythematosus
Alessandra C. Bonfa¹, Luciana P.C. Seguro², Valéria Caparbo³, Eloisa Bonfa³ and Rosa M R Pereira³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Division of Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose To evaluate single nucleotide polymorphisms (SNPs) of the receptor activator of NF-κB ligand (RANKL), RANK and osteoprotegerin (OPG) genes in premenopausal systemic lupus erythematosus…
Abstract Number: 232 • 2014 ACR/ARHP Annual Meeting
Significance of Serum Srankl and Osteoprotegerin Concentration in Patients with Rheumatoid Arthritis
Kotaro Shikano, Kaichi Kaneko, Mai Kawazoe, Shotaro Masuoka, Hiroshi Sato, Emiko Shindo, Natsuki Fujio, Makoto Kaburaki, Sei Muraoka, Nahoko Tanaka, Tatsuhiro Yamamoto, Kenji Takagi, Natsuko Kusunoki, Tomoko Hasunuma and Shinichi Kawai, Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan
Background/Purpose Rheumatoid arthritis (RA) is known as a cause of secondary osteoporosis. The previous studies reported that receptor activator for nuclear factor κB ligand (RANKL)…
Abstract Number: 28 • 2014 ACR/ARHP Annual Meeting
Evidence for Receptor Activator of NF-Kb (RANK)-Independent Bone Erosion in the Cherubism Mouse Model of Inflammatory Arthritis
William R. O'Brien¹, Julia F. Charles², Kelly Tsang¹ and Antonios O. Aliprantis¹, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Rheumatology, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: A gain-of-function mutation in the adaptor Src Homology 3 Binding Protein 2 (SH3BP2) causes Cherubism, a rare pediatric disease marked by aggressive bone remodeling…
Abstract Number: 1890 • 2014 ACR/ARHP Annual Meeting
Consistent Inhibition of Bone Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis
Naoki Ishiguro¹, Yoshiya Tanaka², Hisashi Yamanaka³, Toshiyuki Yoneda⁴, Takeshi Ohira⁵, Naoki Okubo⁶, Harry K. Genant⁷, Desiree van der Heijde⁸ and Tsutomu Takeuchi⁹, ¹Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ²University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Daiich Sankyo Co. Ltd, Tokyo, Japan, ⁶1-2-58, Hiromachi, Daiichi Sankyo Co. Ltd, Tokyo, Japan, ⁷University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Denosumab is a fully human monoclonal antibody (IgG2 subclass) that binds specifically to RANKL, inhibits osteoclast-induced bone resorption by preventing the binding of RANKL…
Abstract Number: 412 • 2014 ACR/ARHP Annual Meeting
Determinants of Radiological Progression in Rheumatoid Arthritis: Relationship with Serum Levels of OPG, RANKL and DKK-1
Carmen Gómez-Vaquero¹, Irene Martín-Esteve¹, Jose Ivorra², Jose Antonio Narvaez³, Javier Hernandez Gañan³, Pedro Alia⁴ and Javier Narváez⁵, ¹Rheumatology Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario y Politécnico La Fe., Valencia, Spain, ³Radiology Department, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁴Clinical Laboratory Service, Hospital Universitari de Bellvitge - IDIBELL, Barcelona, Spain, ⁵Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain
Background/Purpose: Osteoprotegerin (OPG), RANKL, and DKK-1 act as regulators of bone resorption and formation. The uncoupling of bone remodelling that occurs in rheumatoid arthritis (RA)…
Abstract Number: 2800 • 2013 ACR/ARHP Annual Meeting
Dose-Response Effects Of Denosumab, a Novel Subcutaneous RANKL Inhibitor, On The Progression Of Bone Erosion In Japanese Patients With Rheumatoid Arthritis Treated With Methotrexate: Results Of Phase II DRIVE Study – A Twelve Month Placebo Controlled, Randomized, Double Blind Study
Tsutomu Takeuchi¹, Yoshiya Tanaka², Naoki Ishiguro³, Hisashi Yamanaka⁴, Toshiyuki Yoneda⁵, Harry K. Genant⁶ and Désirée van der Heijde⁷, ¹Keio University School of Medicine, Tokyo, Japan, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Institute of Rheumatology Tokyo Women's Medical University, Tokyo, Japan, ⁵Indiana University School of Medicine, Indianapolis, IN, ⁶University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Denosumab is a fully human monoclonal antibody (IgG2 subclass) that binds specifically to RANKL. It inhibits osteoclast-induced bone resorption by preventing the binding of…
Abstract Number: 1857 • 2013 ACR/ARHP Annual Meeting
Identification Of SOX5 and SOX6 As Potent Regulators Of RANKL Expression Contributing To Bone Erosion In Rheumatoid Arthritis and Experimental Arthritis Model
Wenfeng Tan¹, Xiaoke Feng², Lingxiao Xu³, Ke Gan⁴, Fang Wang³, Miaojia Zhang⁵, Hui Wu⁶ and Betty P. Tsao⁷, ¹Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, ²Rheumatology, the First Affiliated Hospital of Nanjing Medical University, China, Nanjing, China, ³Department of Rheumatology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, CHINA., Nanjing, China, ⁴Rheumatology Department, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, ⁵Department of Rheumatology, Jiangsu Provincial People's Hospital, Nanjing, China, ⁶Rheumatology, David Geffen School of Medicine University of California Los Angeles, Los Angeles, CA, ⁷Medicine/Rheumatology, UCLA School of Medicine, Los Angeles, CA
Background/Purpose: We previously reported a RANKLpromoter SNP confers an elevated promoter activity after stimulation via binding to a SOX family transcription factor SOX5 and is…
Abstract Number: 1384 • 2013 ACR/ARHP Annual Meeting
Estimation Of The Effect Of Denosumab On Bone Loss From The Results Of The 12-Month Phase II Study In Patients With Rheumatoid Arthritis (RA) On Background Methotrexate (MTX)
Yoshiya Tanaka¹, Tsutomu Takeuchi², Naoki Ishiguro³, Hisashi Yamanaka⁴, Toshiyuki Yoneda⁵, Harry K. Genant⁶ and Désiréé van der Heijde⁷, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Keio University, Tokyo, Japan, ³Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, Nagoya, Japan, ⁴Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ⁵Indiana University School of Medicine, Indianapolis, IN, ⁶University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, ⁷Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: RANKL is an essential factor for osteoclast differentiation and activation. Denosumab, a fully human monoclonal IgG2 antibody, is a potent inhibitor of RANKL and…
Abstract Number: 2312 • 2012 ACR/ARHP Annual Meeting
Senescent T Cells Promote Bone Loss in Rheumatoid Arthritis
Johannes Fessler¹, Rusmir Husic², Elisabeth Lerchbaum³, Verena Schwetz³, Claudia Stiegler³, Barbara Obermayer-Pietsch³, Winfried B. Graninger⁴ and Christian Dejaco⁵, ¹Rheumatology and Immunology, Medical University Graz, Graz, Austria, ²Rheumatology, Medical University Graz, Graz, Austria, ³Division of Endocrinology and Metabolism, Medical University Graz, Graz, Austria, ⁴Internal medicine/Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁵Rheumatology, Southend University Hospital, Westcliff-on-Sea, United Kingdom
Background/Purpose: To study the influence of aged CD28-T cells on systemic osteoporosis in rheumatoid arthritis (RA) patients. Methods: Prospective, cross-sectional study on 100 patients with…
Abstract Number: 1992 • 2012 ACR/ARHP Annual Meeting
Anti-TNF Therapies Improve Bone Mineral Density At the Lumbar Spine of RA Patients by Decreasing Disease Activity and Suppressing Serum RANKL Levels
Allen P. Anandarajah¹, Jennifer Hossler², Kate Burns³, Kelly Callahan³, Yahui Grace Chiu³ and Jennifer H. Anolik⁴, ¹Dept of Rheumatology, Univ of Rochester Medical Ctr, Rochester, NY, ²Rheumatology, University of Rochester, Rochester, NY, ³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁴Medicine- Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Generalized bone loss (osteoporosis or osteopenia) is more common in patients with rheumatoid arthritis (RA) than in the general population. Recent studies suggest that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].